We used proton magnetic resonance spectroscopic imaging semiovale, and significantly reduced NA/Cho in the lentiform nucleus and parietal cortex. There were no significant ( 1 H-MRSI) 
Introduction
The common clinical picture of progressive supranuclear and Dickson, 1995) . Other relevant features include swollen and achromatic neurons, basophilic argyrophilic and taupalsy includes early postural instability, supranuclear vertical gaze palsy, parkinsonism (bradykinesia and axial more positive ubiquitin-negative inclusions in neurons of the substantia nigra and basal ganglia (subthalamic nucleus, than limb rigidity) not benefiting from levodopa therapy, pseudobulbar palsy and subcortical dementia (Litvan et al., striatum and pallidum), and sometimes along the dentatorubrothalamic tracts (Gibb et al., 1989; Feany and 1996a,c) . Macroscopic neuropathological features of progressive supranuclear palsy are not distinctive and, when Dickson, 1995) . PET studies (Eidelberg et al., 1991; Blin et al., 1992) have demonstrated that most cortical areas are present, are limited to atrophy of the diencephalon and mesencephalon (Lantos, 1994) . Histological abnormalities affected, with the parietal cortex predominating. Among the subcortical structures, the thalamus and the lenticular nucleus are more striking and include mainly neurofibrillary tangles (NFTs), neuropil threads, neuronal loss and gliosis affecting are most affected.
The evidence presented so far shows that progressive the substantia nigra, subthalamic nucleus, nucleus basalis of Meynert, globus pallidus, pretectal region, tegmentum of the supranuclear palsy, Parkinson's disease and corticobasal degeneration share several common clinical and anatomical mid-brain and pons, locus coeruleus, raphe nuclei and the nuclei of various cranial nerves (De Bruin and Lees, 1994;  features. Neuropathologically confirmed cases of progressive supranuclear palsy have been clinically confused with Lantos, 1994) . Preliminary neuropathological criteria have been proposed to distinguish typical, atypical and combined
Parkinson's disease, corticobasal degeneration, multiple system atrophy and Alzheimer's disease (Litvan et al. , progressive supranuclear palsy, on the basis of a regionally specific distribution of NFTs . Recently, 1996c) . In addition, neuropathologically confirmed cases of diffuse Lewy body disease, cerebrovascular disease, prion cortical involvement has been established. Takahashi et al. (1989) , Hauw et al. (1990) and Verny et al. (1996) found disease and corticobasal degeneration have been clinically misdiagnosed as progressive supranuclear palsy (Riley and that the cortex is affected, with NFTs being most frequent in the precentral gyrus. PET studies, recently reviewed by Litvan et al., 1996c) . In recent studies in which retrospectively collected clinical information of autopsy- Brooks (1994) , have also shown a diffuse decrease in cerebral metabolism, with most patients having reduced glucose confirmed cases was presented to neurologists for diagnosis of progressive supranuclear palsy and corticobasal degeneration, metabolism in frontal and striatal areas.
The clinical picture of Parkinson's disease is thought to false positives accounted for up to 50% of the progressive supranuclear palsy diagnoses (Litvan et al., 1996c) , while be better defined (Rajput et al., 1991; Hughes et al., 1992) ; the major pathological process involves the presence of Lewy sensitivity of clinical diagnosis for corticobasal degeneration was 35% (Litvan et al., 1997) . There is a need for a bodies and degeneration of the pigmented neurons of the substantia nigra and adjacent midbrain (Gibb, 1992) . Using noninvasive laboratory procedure that may improve diagnostic accuracy and possibly lead to a more detailed selective criteria (asymmetrical onset, no atypical features and no possible etiology for another parkinsonian syndrome), knowledge of the brain regional involvement in these diseases. the specificity for the diagnosis of Parkinson's disease improves (Hughes et al., 1992) . However, misdiagnosis Proton magnetic resonance spectroscopy ( 1 H-MRS) provides insight into the metabolism of several endogenous frequently occurs with progressive supranuclear palsy and multiple system atrophy, and one out of four prospectively brain chemicals, and has been successfully applied to the study of CNS disorders (Gill et al., 1989; Jackson, 1992 ; followed patients with clinically diagnosed Parkinson's disease at death, has another neuropathological diagnosis Prichard and Brass, 1992; Kruse et al., 1994; Vion-Dury et al., 1994) . The principal metabolite signals detected (Rajput et al., 1991; Hughes et al., 1992) .
Classically, corticobasal degeneration has onset in the sixth by 1 H-MRS at long echo time, are N-acetyl-containing compounds with N-acetylaspartate (NA) as the prominent and seventh decades, with a combination of neurobehavioural features (ideomotor apraxia, alien limb syndrome, aphasia, contributor, followed by compounds containing choline (Cho), creatine-phosphocreatine (Cre) and lactate (Lac). NA hemi-inattention, frontal lobe-type behaviour), movement disorder (asymmetrical akinesia and rigidity, limb dystonia, is thought to be a neuron-specific molecule because it is absent in both mature glial cell cultures and tumours of glial postural instability, focal stimulus-sensitive myoclonus, action tremor) and other manifestations (supranuclear gaze cell origin (Birken and Oldendorf, 1989; Gill et al., 1990; Peeling and Sutherland, 1992; Urenjak et al., 1993) . palsy, pyramidal features, pseudobulbar palsy) (Gibb et al., 1989; Riley et al., 1990; Riley and Lang, 1993; Rinne et al., Immunofluorescence studies have shown that fluorescent anti-NA antibodies colocalize with antibodies against neuron-1994). Pathological features include parietofrontal atrophy with neuronal loss and gliosis, and to a minor extent, nerve specific proteins (Moffett et al., 1991 (Moffett et al., , 1993 . The Cho peak reflects total brain choline stores (Miller, 1991) , with cell loss and gliosis in the lateral thalamic nucleus, globus pallidum, subthalamic nucleus, midbrain tegmentum, major contributions from glycerophosphocholine and phosphocholine (Barker et al., 1994a) . In a recent study substantia nigra and locus coeruleus (Gibb et al., 1989; Feany Miller et al. (1996) reported that the in vivo Cho signal rigidity and bradykinesia, pseudobulbar palsy or dysarthria, frontal-lobe-type dementia and no focal signs. The diagnosis correlated with in vitro measures of cellular density and water soluble Cho compounds (free choline, phosphocholine of one progressive supranuclear palsy patient who later died was neuropathologically confirmed using the preliminary and glycerophosphocholine). The Cre peak reflects the total amount of phosphocreatine and creatine which are involved NINDS (National Institute of Neurological Disorders and Stroke) neuropathological criteria . in energy metabolism (Miller, 1991) . Lac signal rises whenever the glycolytic rate exceeds the capacity of oxidative Parkinson's disease patients met all the following inclusion criteria: (i) parkinsonism characterized by typical resting metabolism or, possibly, when the capacity for exporting lactate to the bloodstream is impaired (Prichard, 1991) .
tremor, bradykinesia and rigidity; (ii) asymmetrical manifestations at onset; (iii) significant response to a satisfactory In Parkinson's disease, previous single-volume 1 H-MRS studies have shown no significant reduction of NA in the trial of levodopa; and (iv) absence of atypical features suggestive of alternate diagnosis. All Parkinson's disease striatum (Holshouser et al., 1995) , putamen and globus pallidum (Davie et al., 1995) and occipital lobe (Bowen patients were optimally treated with antiparkinsonian therapy. Corticobasal degeneration patients were classified according et al., 1995) . A preliminary report (Lemmens et al., 1995) described a significant reduction of NA/Cre in the putamen to modified Lang et al. (1994) their legal guardians, gave written informed consent for the study. 1995a) and enables the spatial extent of metabolic abnormalities to be mapped. The acquired data can be displayed in a tomographic format, thus making multislice 1 H-MRSI suitable to study diffuse CNS disorders and large
MRI
Magnetic resonance imaging (MRI) studies were performed and heterogeneous CNS lesions (Barker et al., 1994b (Barker et al., , 1995 Kruse et al., 1994; Bizzi et al., 1995; Tedeschi et al., 1995b, in a 1.5 Tesla magnet. Axial brain images were obtained using T 1 -weighted pulse sequences with a repetition time 1996a, b).
In the present study, we used multislice 1 H-MRSI to (TR) of 450 ms and an echo time (TE) of 12-16 ms, and T 2 -weighted images with a TR of 4000 ms and a TE of 108 measure, in vivo, the metabolite signal intensities of NA, Cho, Cre and Lac in the brains of patients with progressive ms. These studies were evaluated by an experienced senior neuroradiologist (N.J.P.) who had no knowledge of the supranuclear palsy, Parkinson's disease and corticobasal degeneration. Our purposes were to establish whether subjects' clinical status. The degree of cerebral and cerebellar atrophy was graded as absent, mild, moderate or marked multislice 1 H-MRSI could detect a specific pattern of cortical and subcortical neuronal damage or loss in progressive from the width of the cortical sulci and the size of the ventricles on the T 1 -weighted studies. The presence of supranuclear palsy, Parkinson's disease and corticobasal degeneration; and to evaluate whether it could provide a midbrain and pons atrophy was assessed by measuring their antero-posterior diameters from the axial T 1 -weighted diagnostic aid in the differential diagnosis of these diseases.
sections. Atrophy was established when the patient measurements fell outside the range of previously established normative values.
Subjects and methods
We studied 12 patients with progressive supranuclear palsy, aged 52-82 years; 10 patients with Parkinson's disease, aged 50-72 years; nine patients with corticobasal degeneration
H-MRSI studies
The 1 H-MRSI studies were performed on a 1.5 Tesla MR aged 59-80 years; and 11 age-and sex-matched healthy volunteers as control subjects (Table 1 ). All progressive imager equipped with self-shielded gradients (GE Medical Systems, Milwaukee, Wisc., USA) using a previously supranuclear palsy patients met the Blin et al. (1990) criteria for probable progressive supranuclear palsy with established described data-acquisition procedure and a standard quadrature-imaging head coil . Images validity and reliability (Litvan et al., 1996b) . Briefly, these criteria require the presence of a progressive course, duration were obtained at an angle of~20°from the orbitomeatal line to obtain the maximum number of regions of interest of Ͻ10 years, vertical supranuclear palsy, severe postural instability, absence of response to levodopa therapy, axial throughout the whole brain. Phase-encoding procedures were used to obtain a 32 ϫ 32 array of spectra from voxels four of the five 3-mm MRIs that correspond to the 15-mm 1 H-MRSI; and (ii) voxels showing poor spectral resolution with a nominal volume of 0.84 ml (7.5ϫ7.5ϫ15 mm) within the selected slices. The 1 H-MRSI data acquisition comprised a (less than half-height separation of Cho and Cre signals) or residual water and/or lipid signals were excluded. The regions multiple-slice spin echo slice selection with a TR of 2200 ms and a TE of 272 ms. Outer-volume signal saturation was of interest were chosen by one of us (S.B.), who had no knowledge of the subjects' diagnoses. For each region of used to suppress signals arising from the skull marrow and surface tissues. Four 15-mm thick slices with a 3-mm interest, the mean integrated metabolite signal intensity ratios (NA/Cho, NA/Cre and Cho/Cre) were calculated for the interslice spacing were acquired.
Raw 1 H-MRSI data were processed off-line using software patients and normal subjects. developed at our institution. After Fourier reconstruction, a combination of automated and interactive algorithms was used to identify the location of Cho, Cre, NA and Lac in
Statistical analysis
Metabolic differences between patients and control subjects spectra from each of the individual voxels within the brain. The magnitude of each acquired spectrum was computed, were examined for each region of interest and for each ratio with a 2ϫ2 factor analysis of variance (ANOVA) with the and the signal strength (bounded by 0.05 p.p.m. on either side of the Cho, Cre, NA and Lac signal positions) was following factors: hemisphere (left or right) and diagnoses (patients or control subjects). Post hoc analysis was performed integrated to produce four 32ϫ32 arrays showing spatial variation of the metabolite signal intensities.
by means of the Scheffe test. Bonferroni correction for multiple regions was applied. In the corticobasal degeneration Conventional 3-mm T 1 -and T 2 -weighted MRIs, collected immediately after the 1 H-MRSI acquisition, were used to patients, we performed a within-subjects ANOVA to test for differences between regions of interest contralateral and identify the regions of interest encompassing defined neuroanatomical structures within the brain. Regions of interest ipsilateral to the more affected side. Factorial ANOVA (regions, diagnoses and side) was used to assess group containing an integral number of 0.84-ml spectroscopic voxels were drawn on the T 1 -weighted and T 2 -weighted MRIs and differences in the pattern of 1 H-MRSI abnormalities for individual metabolite ratios (NA/Cre, NA/Cho and Cho/Cre). transferred to the identical location on all 1 H-MRSI, to obtain metabolite signal intensities in these locations. Regions of interest were selected from the brainstem, caudate, lentiform nucleus, thalamus, centrum semiovale, and from the frontal, Figure 1 shows the location of the regions of interest parietal, precentral, temporal and occipital cortices, according to the following criteria: (i) the regions of interest should fit and the corresponding representative spectra in one control subject. Figure 2 shows a selected section of the 1 H-MRSI entirely within the same neuroanatomical structure in at least (7.5ϫ7.5 mm), using a colour scale which depicts the strongest signal integral with red and the weakest with dark blue. The 1 H-MRSI images are scaled to the highest value of any of the metabolite signal intensities for each 1 H-MRSI slice, so that the regional distribution of metabolite signal intensities can be compared within the same slice, although colour images from the same anatomical location cannot be compared in different subjects or in different slice. The data are presented as means Ϯ SD. For abbreviations of regions of interest, see Fig. 1 . Significant differences between controls and progressive supranuclear palsy patients and between controls and corticobasal degeneration patients are indicated. *P Ͻ 0.05; **P Ͻ 0.01; ***P Ͻ 0.001. and the corresponding MRI of one control ( Fig. 2A ) and one palsy patients had a significantly reduced (all these comparisons used Bonferroni corrected ANOVA) NA/Cre progressive supranuclear palsy patient (Fig. 2B) . 1 H-MRSI data are displayed at their nominal voxel in-plane resolution value in the brainstem [F(3, 27) ϭ 6.29], centrum semiovale [F(3,62) ϭ 6.49], and frontal [F(3, 56) ϭ 5.57] and precentral (7.5ϫ7.5 mm), using a colour scale which depicts the strongest signal integral with red and the weakest with dark cortices [F(1,25) ϭ 10.45], and a significantly reduced (Bonferroni corrected ANOVA) NA/Cho value in the blue. The 1 H-MRSI images are scaled to the highest value of any of the metabolite signal intensities for each 1 H-MRSI lentiform nucleus [F(3,51) ϭ 7.64]. Compared with control subjects, progressive supranuclear palsy patients showed a slice so that the regional distribution of metabolite signal intensities can be compared within the same slice, although trend to a reduced (Bonferroni corrected ANOVA) NA/Cre value (P Ͻ 0.07) in the lentiform nucleus, and a reduced colour images from the same anatomical location cannot be compared in different subjects or in different slices. In the NA/Cho value (P Ͻ 0.07) in centrum semiovale and precentral cortex. Compared with control subjects, corticobasal present study, the images did not allow us to identify a pattern of regional abnormalities in any patient group. The degeneration patients had a significantly reduced (Bonferroni corrected ANOVA) NA/Cre value in the centrum semiovale selected 1 H-MRSI sections are presented to show the regional volume resolution of 1 H-MRSI and are not representative of [F(3,62) ϭ 6.49], and significantly reduced (Bonferroni corrected ANOVA) NA/Cho value in the lentiform nucleus the whole patient group.
Results
The 1 H-MRSI findings (mean Ϯ SD) are reported in The present multislice 1 H-MRSI study showed a regionally and parietal cortex, and a reduced NA/Cho value (P Ͻ specific pattern of neuronal involvement in progressive 0.07) in the centrum semiovale. There were no significant supranuclear palsy patients, as revealed by a significant differences between Parkinson's disease patients and control reduction of NA/Cre and NA/Cho in the brainstem, lentiform subjects, or between individual patient groups in any region nucleus, centrum semiovale and frontal cortex (compared with of interest. No significant differences in Cho/Cre values were the control subjects), and in corticobasal degeneration patients, found in any region of interest for any comparison. No as revealed by a significant reduction of NA/Cre and NA/Cho significant side-to-side differences were found in any region in lentiform nucleus, centrum semiovale and parietal cortex of interest, in any metabolite signal, for control subjects, (compared with the control subjects). In corticobasal Parkinson's disease or progressive supranuclear palsy degeneration patients, NA/Cho was significantly reduced in patients. However, in corticobasal degeneration patients, the parietal cortex contralateral to the most affected side. We NA/Cho was significantly reduced in the parietal cortex found statistically significant group differences in regional contralateral to the most affected side [F(2,00) ϭ 33.77, patterns of NA/Cre and NA/Cho, between normal control P Ͻ 0.03]. No Lac signals were found in the patients or subjects and all patient groups, between Parkinson's disease normal subjects.
and corticobasal degeneration, and between Parkinson's Overall, the regional pattern of NA/Cre was significantly disease and progressive supranuclear palsy. different among the studied disorders (P Ͻ 0.001, factorial
An accurate comparison of our results with pathological and ANOVA). The regional pattern of NA/Cre reduction was PET findings is difficult because the degree to which in vivo different in progressive supranuclear palsy patients versus spectroscopy and histochemistry, and glucose consumption are normal control subjects (P Ͻ 0.0001); Parkinson's disease comparable is uncertain. Nevertheless, our results are in good patients versus normal control subjects (P Ͻ 0.01); topographical agreement with previous neuropathological and corticobasal degeneration patients versus normal control PET studies in progressive supranuclear palsy and corticobasal subjects (P Ͻ 0.0001); Parkinson's disease versus degeneration (Gibb et al., 1989; Takahashi et al., 1989 ; Hauw progressive supranuclear palsy (P Ͻ 0.01); and Parkinson's et al., 1990; Eidelberg et al., 1991; Blin et al., 1992 ; Brooks, disease versus corticobasal degeneration (P Ͻ 0.001).
1994; De Bruin and Lees, 1994; Hauw et al., 1994 ; Lantos, NA/Cre reduction tended to be asymmetrical only in 1994; Verny et al., 1996) , and they demonstrate that 1 H-MRSI Parkinson's disease and corticobasal degeneration (P Ͻ 0.06).
can detect a regional pattern of neuronal loss or degeneration The regional pattern of NA/Cho reduction was significantly in these diseases. Furthermore, the differences in the regional different between normal control subjects and progressive patterns of 1 H-MRSI abnormalities suggest that this technology supranuclear palsy patients (P Ͻ 0.0001), normal control may be helpful in the differential diagnosis of parkinsonian subjects and corticobasal degeneration patients (P Ͻ 0.0001), syndromes. Parkinson's disease and progressive supranuclear palsy
The structural MRI analysis of our progressive supranuclear (P Ͻ 0.03), and Parkinson's disease and corticobasal palsy patients showed a high frequency of midbrain atrophy degeneration (P Ͻ 0.0001). A trend was found for regional (11 out of 12 patients). This frequency is higher than previously differences in NA/Cho between normal control subjects and reported (Savoiardo et al., 1994) and is particularly valuable Parkinson's disease patients (P ϭ 0.06), and progressive since progressive supranuclear palsy patients overall presented supranuclear palsy and corticobasal degeneration (P ϭ 0.06).
at a relatively early stage of the disease (mean, 4 years after The regional pattern of Cho/Cre abnormalities was symptom onset). Even though this was not the central thrust of significantly different between normal control subjects and the present investigation, it is worth underlining the fact that corticobasal degeneration patients (P Ͻ 0.01), and MRI could qualitatively differentiate progressive supranuclear Parkinson's disease and corticobasal degeneration (P Ͻ 0.01).
palsy from the other diseases. In the control group, none of the subjects showed cerebral atrophy but one showed mild cerebellar atrophy; in this group the range of the anteroposterior diameter of the midbrain was 14-18 mm, and that of the pons was 24-28 mm. In the
Progressive supranuclear palsy
Our results suggest the occurrence of neuronal loss or progressive supranuclear palsy group, seven patients had mild, and one had moderate, cerebral atrophy, three patients had mild degeneration in the lentiform nucleus and brainstem, as revealed by the significant reduction of NA/Cre and/or NA/ cerebellar atrophy, eleven patients had an atrophic midbrain, and seven had an atrophic pons. In the Parkinson's disease Cho, and are consistent with the well-known preferential involvement of the globus pallidum and midbrain in the disease group, four patients had mild cerebral atrophy, none had cerebellar atrophy, all had normal midbrain, and two had a Daniel et al., 1995) . Due to the small volume of the latter two structures, we purposely selected the mildly atrophic pons. In the corticobasal degeneration group, three patients had moderate and five had mild cerebral atrophy, lentiform nucleus (including the pallidum as well as the less affected putamen) and brainstem (including the midbrain as none had cerebellar atrophy, and all had normal midbrain and pons.
well as the less-affected pons and medulla oblongata), respectively, so that the present 1 H-MRSI findings from the metabolism in the substantia nigra, the initially involved, and most affected, Parkinson's disease brain area. Indeed, due to lentiform nucleus and brainstem are likely to be an underestimate due to partial volume effects. The significantly its small volume, our brainstem findings are probably influenced by partial volume effect. reduced NA in the frontal and precentral cortex is particularly relevant, since it supports the involvement (in the form of neuronal loss or degeneration) of the cerebral cortex in the disease. Neuropathological studies (Takahashi et al., 1989;  Corticobasal degeneration Hauw et al., 1990; Verny et al., 1996) showed that neocortical Our results suggest the occurrence of neuronal loss or NFTs are more frequent in the precentral gyrus than the degeneration in the parietal cortex, lentiform nucleus and association areas, while PET studies (Brooks, 1994) found the centrum semiovale, as revealed by the significant reduction of frontal areas to be the most affected. The present 1 H-MRSI NA/Cho and/or NA/Cre. Although not significant, there was a study suggests that neuronal loss or degeneration occurs in trend (P Ͻ 0.07) towards a reduction of NA/Cho in the frontal both the frontal association and motor (precentral cortex) areas, cortex. These results are consistent with neuropathological even at a relatively early stage of the disease. Finally, the studies, in showing the preferential involvement of the parietal significantly reduced NA in the centrum semiovale suggests and frontal cortex, and basal ganglia (Gibb et al., 1989 ; that the axons projecting from the basal ganglia to the cortices Eidelberg et al., 1991; Blin et al., 1992) . The significant through the white matter may also be affected. This finding is reduction of NA/Cho in the lentiform nucleus may be an consistent with light microscopic immunohistochemical data underestimate because of contamination of the affected that showed extensive involvement of axons present in the globus pallidum with the spared putamen. Although not white matter that interconnect subcortical nuclei (Probst significant, brainstem NA/Cre and NA/Cho were, as expected, et al., 1988) .
reduced. The significant reduction of NA/Cre in the centrum semiovale suggests that the axons interconnecting subcortical nuclei with cortices may also be degenerating. The comparison
Parkinson's disease
between the affected and unaffected sides showed a statistically We were unable to demonstrate a significant group reduction significant difference in the parietal cortex for NA/Cho. The of NA/Cre and NA/Cho in any individual region of interest, limited discriminating power between more and less affected which is in keeping with pathological studies in Parkinson's side can be due to the relatively small number of bilateral disease that revealed neuronal preservation in the lentiform regions of interest available. The significant asymmetries of nucleus (Oppenheimer and Esiri, 1992) . The present findings NA/Cho in the parietal cortex is in keeping with are in agreement with previous single-volume 1 H-MRS studies neuropathological and PET studies showing this feature to be that showed no significantly reduced NA in the striatum one of the landmarks of corticobasal degeneration (Gibb et al., (Holshouser et al., 1995) , putamen and globus pallidum (Davie 1989; Eidelberg et al., 1991; Blin et al., 1992 Blin et al., ). et al., 1995 , or occipital lobe (Bowen et al., 1995) of Parkinson's disease patients. However, a significant reduction of NA/Cre in the putamen of Parkinson's disease patients Between-group comparisons and methodological on long-term levodopa therapy complicated by severe motor fluctuations (Lemmens et al., 1995) and a significant reduction considerations In the present 1 H-MRSI study, there were no significant of NA/Cho were also found in a subset of elderly Parkinson's disease patients (Holshouser et al., 1995) . The latter findings differences between progressive supranuclear palsy, Parkinson's disease and corticobasal degeneration in any (Holshouser et al., 1995; Lemmens et al., 1995) suggest that cases of advanced Parkinson's disease might be associated individual region of interest. This negative finding could reflect the limitations of estimating metabolite changes with with more pronounced neuronal damage. The differences between the present results and the earlier ones might reflect ratios when there is a simultaneous change of two or more metabolites. Moreover, the changes in NA are in the same differences in the choice of the regions of interest or in severity of the disease; most of our Parkinson's disease patients were direction in all the diseases studied, which further diminishes the sensitivity of the method. While some form of absolute still good levodopa responders. Bowen et al. (1995) in a single-voxel (27-ml volume) 1 Hquantification would be desirable, it is not always practically accomplished. Absolute quantification requires additional MRS study found a significant increase of Lac/NA in the occipital lobe of Parkinson's disease patients. This finding was measurements beyond those made here. Such measurements would require considerable additional time, and patients cannot thought to support the hypothesis that Parkinson's disease is a systemic disorder characterized by impaired oxidative energy always tolerate examinations longer than that used here. Finally, because of the small volume of some brain areas that are metabolism. Lac was not detected in the basal ganglia in the other 1 H-MRS studies (Davie et al., 1995; Holshouser et al., representative of the actual disease process (e.g. the substantia nigra in Parkinson's disease), partial volumes, combined with 1995; Lemmens et al., 1995) or in the basal ganglia as well as several other regions of interest in the present 1 H-MRSI study.
surrounding nonaffected structures, have contaminated the spectroscopic findings. However, we cannot rule out an impaired oxidative energy Nevertheless, significant differences between normal T 2 relaxation times in patients with progressive supranuclear palsy, Parkinson's disease and corticobasal degeneration; control subjects and all patient groups, between Parkinson's disease and progressive supranuclear palsy, and between therefore, we cannot exclude either T 1 or T 2 effects on calculated ratios. The good regional concordance between the Parkinson's disease and corticobasal degeneration, were found in the regional pattern of NA/Cre and NA/Cho reduction, 1 H-MRSI findings and neuronal loss in pathological studies suggests that the present 1 H-MRSI findings in progressive whereas the ratio NA/Cho showed a trend toward a significant difference between progressive supranuclear palsy and supranuclear palsy and corticobasal degeneration are true results rather than the effect of a parallel pattern of changes in corticobasal degeneration. The present results highlight the major advantage of 1 H-MRSI, i.e. the ability to evaluate T 1 or T 2 of 1 H-MRSI metabolites. Due to the extensive folding of the thin cortical gray matter the metabolite signal intensities from many brain regions simultaneously. By doing this, it is possible to detect a pattern ribbon with white matter, cortical spectroscopic voxels, even of the order of 0.84 ml, may contain a mixture of both tissue of abnormalities that may prove helpful in the differential diagnosis of these diseases. On the other hand, the occurrence types. Because cerebral atrophy was present in some patients, some spectroscopic voxels could also be contaminated with of significant group differences does not imply that 1 H-MRSI can be used to differentiate between individual patients. We different amounts of CSF. However, even if a markedly greater amount of CSF was present in the selected regions of interest of anticipate that further technological improvements (i.e. quantitative measurements and reduced voxel size) may lead the patients, all metabolite signals would be equally decreased, thereby not affecting metabolite ratios. to an increased sensitivity of 1 H-MRSI in the differential diagnosis of parkinsonian syndromes.
Errors in voxel localization can creep in from a variety of sources which are too numerous to discuss in detail. During Nevertheless, even if the specificity of the clinical diagnosis of 195: 58-64. progressive supranuclear palsy using the Blin et al. (1990) criteria is high, particularly at early stages (Litvan et al., 1996c) 
